This tender is from the country of Belgium in Europe region. The tender was published by Cliniques universitaires Saint Luc, Clinique Saint-Pierre Ottignies, Clinique Saint-Jean, Cliniques de l'Europe on 18 Dec 2025 for Belgium Antineoplastic and immunomodulating agents Pomalidomide. The last date to submit your bid for this tender is 12 Feb 2026. This tender is for the companies specializing in Antineoplastic and immunomodulating agents and similar sectors.
Tender Organisation:
Cliniques universitaires Saint Luc, Clinique Saint-Pierre Ottignies, Clinique Saint-Jean, Cliniques de l'Europe
Tender Sector:
Tender Service:
Worldwide
Tender Region:
Tender Country:
Tender CPV:
33652000 : Antineoplastic and immunomodulating agents
Tender Document Type:
Tender Notice
Tender Description:
Belgium Antineoplastic and immunomodulating agents Pomalidomide
Tender Bidding Type:
Tender Notice No:
Tender Document:
Looking for more tenders like this one in Antineoplastic and immunomodulating agents? With over 70 million global procurement opportunities and new tenders added daily, Tender Impulse is your gateway to international and local contracting success. Whether you're targeting the Healthcare & Medical sector in Belgium, or expanding across regions, we provide live, accurate, and relevant updates every day.
Our platform sources tenders from:
Every day, we add hundreds of new RFPs, RFQs, EOIs, and contract awards across multiple sectors and geographies. This tender from Belgium is just a sample of what's available right now.
Tender Impulse covers:
Each listing is categorized using CPV codes like 33652000, enabling precise filtering. Search by:
While you're viewing a tender in Belgium, Tender Impulse offers access to tenders across:
Tender Impulse provides more than listings:
Thousands of new tenders are added daily-across countries, sectors, and CPV codes. With Tender Impulse, you gain strategic insight, timely alerts, and a competitive edge.
Start your free trial to unlock tenders customized to your Healthcare & Medical, Belgium, and Antineoplastic and immunomodulating agents categories.